Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prilosec 1 Labeling Studies Lead To Fall 2003 Launch Target

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble plans to introduce its nonprescription version of AstraZeneca's Prilosec (omeprazole) in the fall of 2003 based on the expectation it will obtain FDA approval for the switch in the year's third quarter

You may also be interested in...



P&G Crest Night Effects Positioned As Superior Paint-On Whitener

Procter & Gamble's latest response to the growing competition in the tooth-whitening category is the launch of Crest Night Effects, a lower-priced, paint-on whitener scheduled to reach shelves in March

P&G Crest Night Effects Positioned As Superior Paint-On Whitener

Procter & Gamble's latest response to the growing competition in the tooth-whitening category is the launch of Crest Night Effects, a lower-priced, paint-on whitener scheduled to reach shelves in March

P&G Crest Night Effects Positioned As Superior Paint-On Whitener

Procter & Gamble's latest response to the growing competition in the tooth-whitening category is the launch of Crest Night Effects, a lower-priced, paint-on whitener scheduled to reach shelves in March

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel